Quarterly report pursuant to Section 13 or 15(d)

2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.20.1
2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 05, 2020
Jan. 31, 2020
Oct. 31, 2019
Aug. 12, 2019
Jul. 31, 2019
Jan. 31, 2019
Oct. 31, 2018
Jul. 31, 2018
Jan. 31, 2020
Jan. 31, 2019
Apr. 30, 2019
Intangible assets   $ 3,549,427             $ 3,549,427   $ 3,549,427
Impairment of intangible assets                 0 $ 0  
Impairment of long-lived assets                 $ 0 0  
U.S. federal income tax rate                 21.00%    
Research and development costs   113,296       $ 59,144     $ 203,566 442,039  
Uninsured cash balances   0             0   127,000
Accumulated deficit   (103,107,876)             (103,107,876)   $ (100,031,371)
Net loss   (875,308) $ (1,067,122)   $ (1,134,075) $ (676,347) $ (1,036,574) $ (1,215,363) (3,076,505) $ (2,928,284)  
Block Trade [Member]                      
Proceeds from the sale of equity       $ 884,000              
Block Trade [Member] | Subsequent Event [Member]                      
Proceeds from the sale of equity $ 186,000                    
Private Placement [Member]                      
Proceeds from the sale of equity   450,000                  
Private Placement [Member] | Subsequent Event [Member]                      
Proceeds from the sale of equity $ 65,000                    
Cell-in-a-Box [Member]                      
Intangible assets   1,549,427             1,549,427    
Diabetes License [Member]                      
Intangible assets   $ 2,000,000             $ 2,000,000    
SG Austria [Member]                      
Percentage investment in SG Austria   14.50%             14.50%